European Pharmaceutical Review

NOVEMBER 8, 2022

2) limiting the scope and number of patents asserted in litigation against proposed biosimilar entrants. 3) policing anticompetitive settlements between competing drug manufacturers. 4) prohibiting ‘product hopping’ and interference with generic and biosimilar substitutions. 5) monitoring access to biosimilars.

Biosimilars 52

Biosimilars Drug Pricing Pharmaceutical Manufacturing Pharmaceutical Companies 52

FDA Law Blog: Biosimilars

MARCH 6, 2024

His practice supports clients throughout the life sciences from biotech startups and multinational pharmaceutical companies to CROs and academic researchers to patient advocacy organizations.

Pharmaceutical Manufacturing 59

Pharmaceutical Manufacturing Drug Development Pharmaceutical Companies Pharmaceutical Companies 59

Express Pharma

AUGUST 13, 2024

With growing awareness of the environmental impact of pharmaceutical manufacturing—such as pollution from toxic discharges—companies must adopt more sustainable practices. One of the primary challenges the industry faces is the inherent resource intensity of pharmaceutical manufacturing.

Pharmaceutical Manufacturing 64

Pharmaceutical Manufacturing Packaging Biosimilars Pharmaceutical Companies 64

PharmaShots

FEBRUARY 27, 2023

The speakers shared their views on the topic: Dr. Jagadeesh Babu Rangisetty- “COVID has taught us so many things and the pharmaceutical company has gone through a lot of challenges and at the same time opportunities. According to me the main issue faced during the pandemic was the supply chain of pharmaceuticals.

Biosimilars 40

Biosimilars Diabetes Packaging Hospitals 40